GlassScriptPhysician profile
Colleen Gaughan
NPI 1780611145
$8,785.77
in general payments reported to CMS, 2019-2025
15 companies · $6,470 in 2025
The $6,470 reported for 2025 was more than what 85% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2022: $495 · 2023: $669 · 2024: $912 · 2025: $6,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,417 · Consulting Fee: $2,000 · Travel and Lodging: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,416.77 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $634.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| On Target Laboratories, INC | $5,460.06 | 2024-2025 | Cytalux |
| Atricure, INC. | $731.10 | 2019-2025 | Synergy Ablation System, Atricure Cryoice Cryosphere Cryoablation System, Atricure Cryoice Cryoablation System (Cryo2) |
| Ethicon INC. | $725.90 | 2022-2025 | Monarch Platform |
| Intuitive Surgical, INC. | $613.17 | 2019-2025 | |
| Arthrex, INC. | $292.20 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $195.91 | 2023-2025 | Tezspire, Imfinzi, Tagrisso |
| Boston Scientific Corporation | $161.07 | 2023-2024 | Acquire |
| Enterra Medical, INC. | $152.47 | 2024 | |
| La Jolla Pharmaceutical Company | $128.60 | 2023 | Giapreza |
| Medical Device Business Services, INC. | $110.68 | 2023-2024 | Monarch, Echelon Flex |
| Heron Therapeutics, INC. | $70.15 | 2024 | Zynrelef |
| Reel Surgical, INC. | $63.55 | 2025 | |
| Ambu INC. | $31.55 | 2025 | |
| Abiomed | $27.50 | 2024 | Impella |
| Pacira Pharmaceuticals Incorporated | $21.86 | 2024 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Gaughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.